Atlas Trials

The Effect of Rivaroxaban in Sickle Cell Disease

Clinical trial NCT02072668 · COMPLETED

Trial details

NCT number
NCT02072668
Sponsor
University of North Carolina, Chapel Hill
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Sickle Cell AnemiaSickle Cell-Beta0-Thalassemia
Start date
2014-02-01
Primary completion
2018-10-04
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.